There is substantial evidence that genetic events are associated with the etiology of brain tumors. The purpose of this study is to characterize the cancer risk in a large number of kindreds of glioma patients using combined epidemiologic and statistical techniques and incorporating molecular genetic markers. We will continue to accrue families to obtain a sufficiently large sample size to have precise estimates of the heritable component of gliomas. Several types of analyses will be performed on the data set. First, a descriptive analysis to detect overall cancer excess or excess of specific sites by computing Standardized Incidence Ratios (SIRs). The SIRs will determine whether excess cancer exists in first-degree relatives of glioma patients, by specific site, or by specific proband or relative characteristics. The next type of analysis is hypothesis testing using segregation analysis (with the computer program, Statistical Analysis for Genetic Epidemiology - SAGE) to determine the genetic model and parameter estimates that characterize the mode of inheritance of gliomas and identify specific kindreds showing evidence for a major gene to include in linkage analysis. Through linkage candidate gene analysis we will determine if mutations at distinct cancer predisposing loci are etiologically relevant and inherited from an antecedent relative. The candidate gene analysis will be conducted by Dr. Peter O'Connell at The University of Texas Health Science Center at San Antonio. With a larger sample we will be able to confirm our finding that patients with multifocal glioma, gliomas as a second malignancy, and a family history constitute a genetically predisposed subgroup. This study will be the first comprehensive evaluation of familial aggregation in families of unselected glioma patients. In addition, we are collecting blood from each new patient and our specimen repository will be available to study future candidate genes to integrate with the family data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055261-05
Application #
6237238
Study Section
Project Start
1997-02-17
Project End
1998-01-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Liu, Yanhong; Shete, Sanjay; Hosking, Fay et al. (2010) Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev 20:239-44
Puduvalli, V K; Sampath, D; Bruner, J M et al. (2005) TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233-43
Levin, Victor A; Hess, Kenneth R; Choucair, Ali et al. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981-90
Puduvalli, Vinay K; Hashmi, Masood; McAllister, Leslie D et al. (2003) Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259-66
Wrensch, Margaret; Minn, Yuriko; Chew, Terri et al. (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278-99
Berrak, Su Gulsun; Ozek, Memet M; Canpolat, Cengiz et al. (2002) Association between DNA content and tumor suppressor gene expression and aggressiveness of atypical teratoid/rhabdoid tumors. Childs Nerv Syst 18:485-91
de Andrade, M; Barnholtz, J S; Amos, C I et al. (2001) Segregation analysis of cancer in families of glioma patients. Genet Epidemiol 20:258-70
Steck, P A; Lin, H; Langford, L A et al. (1999) Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 24:135-43
Groves, M D; Maor, M H; Meyers, C et al. (1999) A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45:127-35
Hess, K R (1999) Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:227-31

Showing the most recent 10 out of 36 publications